Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical, Inc.
- Cell-Ess Serum Replacement cell culture medium,
- Cryo-Ess cryopreservation medium, and
- Clin-Ess transportation medium.
"The quality and consistency of Cell-Ess, Cryo-Ess and Clin-Ess gives scientists the confidence to conduct their research without testing each new serum lot purchased, resulting in improved laboratory efficiency and valuable cost savings," said Allan Weber, chief executive officer of Essential Pharmaceuticals. "Moreover, we believe that the characteristics of these media products offer important clinical benefits, making Cell-Ess the ideal choice for use in the cutting edge areas of stem cell, cancer and vaccine research, and Clin-Ess in the preservation of limbs and organs for surgical applications."
The Cell-Ess, Cryo-Ess and Clin-Ess family offers researchers the advantage of superior performance compared to fetal bovine serum. They are free of all animal components and dimethyl sulfoxide (DSMO), do not crystallize or form ice during the thawing process, resulting in less DNA and RNA degradation and fewer artifacts than those preserved using conventional methods. Further, they have demonstrated synthetic reproducibility with no lot-to-lot variability.
Essential Pharmaceuticals acquired exclusive worldwide rights to these media products, originally the LiforCell® family of products, from Lifeblood Medical, Inc. These cell culture and cryopreservation products have been re-branded to correlate to their specific research and clinical applications.
"Essential Pharmaceuticals is known for its outstanding customer support in highly specialized fields," stated Joseph Fischer, President and Chief Executive Officer of Lifeblood Medical. "That, along with the superior advantages of these cell culture and cryopreservation media, will generate increased growth and market penetration of the Lifeblood technology."
About Essential Pharmaceuticals
Essential Pharmaceuticals LLC, a key company in the organ transplant arena, provides Custodiol® HTK organ preservation solution to the transplant medical community. Essential is well-known for excelling in highly specialized medical areas through a combination of outstanding customer support coupled with customized distribution systems and ongoing research projects to further knowledge in the field of organ preservation. Essential plans on bringing this proven model to support medical researchers and further their projects, improving future medical discoveries globally.
For additional information about Essential Pharmaceuticals new family of cell media products, or any other Essential product, please visit our website at www.essentialpharma.com, e-mail to info@essentialpharma.com or call 1-267-757-0112.
*CUSTODIOL® HTK is a registered trademark of Dr. Franz Kohler Chemie GmbH, Alsbach-Hahnlein, Germany.
*LiforCell® is a registered trademark of Lifeblood Medical, Inc.
SOURCE Essential Pharmaceuticals, LLC